AstraZeneca PLC - American Depositary Shares (NQ:AZN)

Both stocks are speculative, but one may stand out as the less risky choice.

Better Artificial Intelligence Stock: IonQ vs. D-Wave Quantum ↗

February 02, 2026

Performance

52-Week Range 51.9% below 52-week high

92.77

160.9652W Low 193.0252W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $160.96 and $193.02 over the past 52 weeks and last traded at $92.77, 51.9% below its 52-week high.

Past 12 Months

N/A

-49.3%

-45.0%

YTD -$90.37

1Y -$75.95

AZN was -45.0% over the past year, -49.3% year to date.

12 Months vs Market

AZN

-45.0%

DIA

+10.1%

SPY

+15.1%

QQQ

+24.3%

IWM

+16.1%

Over the past 12 months AZN returned -45.0% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

Volume & Liquidity

YTD

4.6M

3.1M

More News

AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing

January 20, 2026

AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate ↗

January 20, 2026

Via Chartmill

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline ↗

January 13, 2026

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Why Did EBS Stock Fall 13% Today? ↗

January 15, 2026

The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company) ↗

January 15, 2026

Retail’s Tech Coronation: Walmart Joins the Nasdaq-100 Following Historic Exchange Pivot

Records, Subpoenas, and $4,600 Gold ↗

January 13, 2026

Via Chartmill

January 12, 2026

Walmart (WMT) Hits All-Time High as Investors Pivot to Consumer Defensive Giants

January 12, 2026

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

AMD Ignites the ‘Yotta-Scale’ Era: Unveiling the Instinct MI400 and Helios AI Infrastructure at CES 2026

January 08, 2026

Via TokenRing AI

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

January 08, 2026

From AstraZeneca

Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge

January 02, 2026

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Is IonQ Stock a Buy Now? ↗

December 30, 2025

The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗

December 29, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗

December 23, 2025

Via Chartmill

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

Via PredictStreet

December 22, 2025

From AstraZeneca

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗

December 18, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

December 15, 2025

From AstraZeneca